Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

aTYR PHARMA (ATYR) Invested Capital (2019 - 2025)

Historic Invested Capital for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $80.2 million.

  • aTYR PHARMA's Invested Capital rose 2317.51% to $80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.2 million, marking a year-over-year increase of 2317.51%. This contributed to the annual value of $70.0 million for FY2024, which is 2276.58% down from last year.
  • Latest data reveals that aTYR PHARMA reported Invested Capital of $80.2 million as of Q3 2025, which was up 2317.51% from $74.8 million recorded in Q2 2025.
  • aTYR PHARMA's 5-year Invested Capital high stood at $117.4 million for Q3 2021, and its period low was $40.8 million during Q2 2021.
  • In the last 5 years, aTYR PHARMA's Invested Capital had a median value of $81.4 million in 2024 and averaged $83.5 million.
  • Per our database at Business Quant, aTYR PHARMA's Invested Capital surged by 24660.78% in 2021 and then crashed by 3467.73% in 2022.
  • aTYR PHARMA's Invested Capital (Quarter) stood at $109.1 million in 2021, then tumbled by 34.68% to $71.3 million in 2022, then rose by 27.18% to $90.7 million in 2023, then decreased by 22.77% to $70.0 million in 2024, then grew by 14.59% to $80.2 million in 2025.
  • Its Invested Capital stands at $80.2 million for Q3 2025, versus $74.8 million for Q2 2025 and $75.0 million for Q1 2025.